胸大肌肌皮瓣在头颈部肿瘤术后组织缺损修复中的应用

目的 总结胸大肌肌皮瓣在头颈部肿瘤术后组织缺损修复中的应用。方法 1992年10月至2001年12月，对80例头颈肿瘤患者应用81块胸大肌肌皮瓣进行一期组织修复。结果 全组肌皮瓣完全存活71块。2块肌皮瓣皮肤完全坏死。8块肌皮瓣皮肤远端轻度坏死。结论 胸大肌肌皮瓣血供可靠，修复操作简单，用途广泛，能满足头颈部肿瘤术后缺损的修复。     

胸大肌肌皮瓣Ⅰ期修复头颈部肿瘤术后缺损—附25例临床分析

对胸大肌肌皮瓣在25例头颈中肿瘤术后缺损修复中应用的临床资料进行总结分析,25例患者中,2例皮瓣出现不同程度的坏死,1例完全坏死（占12％）,其他均完全成活,胸大肌肌皮瓣修复头颈部肿瘤术后缺损成活率高,可广泛应用于头颈部各个部位。     

胸大肌肌皮瓣在晚期口腔颌面肿瘤术后修复中的应用

目的　探讨胸大肌肌皮瓣在晚期口腔颌面肿瘤术后缺损修复中的应用。方法　对 6 6例口腔颌面部肿瘤术后应用胸大肌肌皮瓣进行一期修复病例进行总结分析。结果　胸大肌肌皮瓣皮肤完全坏死 1例 ,皮肤远端部分坏死 5例 ,完全成活率为 90 9%。结论　胸大肌肌皮瓣血供丰富 ,成活率高 ,操作简单 ,是口腔颌面肿瘤术后缺损修复的理想材料     

胸大肌肌皮瓣在头颈部手术缺损修复中的应用

 目的 寻找一种头颈部大面积手术后缺损的修复手段。方法 回顾山西省肿瘤医院头颈科自1985年以来在头颈部大面积手术缺损后进行的胸大肌肌皮瓣修复患者77例。结果 77例胸大肌肌皮瓣修复中72例成活，其中边缘坏死2例，感染6例；全部坏死5例。近5年来成活率为100 ％（18／18）。结论 在头颈部肿瘤手术造成的大面积缺损病例中，胸大肌肌皮瓣是一种用途很广的重要修复手段。     

胸大肌肌皮瓣在晚期口腔颌面肿瘤术后修复中的应用

目的：探讨胸大肌肌皮瓣在晚期口腔颌面肿瘤术后缺损修复中的应用。方法：对66例口腔颌面部肿瘤术后应用胸大肌肌皮瓣进行一期修复病例进行总结分析。结果：胸大肌肌皮瓣皮肤完全坏死1例，皮肤远端部分坏死5例，完全成活率为90．9％。结论：胸大肌肌皮瓣血供丰富，成活率高，操作简单，是口腔颌面肿瘤术后缺损修复的理想材料。     

胸大肌肌皮瓣在晚期头颈肿瘤手术中的应用

目的探讨胸大肌肌皮瓣在晚期头颈肿瘤手术中的应用。方法应用胸大肌肌皮瓣一期修复晚期头颈肿瘤术后缺损262例（其中折叠瓣17例修复口内外穿通性缺损,20例胸大肌肌膜瓣修复口内缺损,5例胸大肌皮瓣联合游离植皮修复咽瘘,5例胸大肌肌皮瓣联合游离皮瓣双瓣修复颌面部洞穿性缺损）。舌再造62例,修复口咽53例,修复口底41例,修复口颊24例,修复颈部31例,修复下咽缺损22例,修复腮腺区缺损29例。结果262例肌皮瓣252例全部成活,8例皮瓣部分坏死肌瓣成活,2例肌皮瓣完全坏死,总的成活率为99.2%（260/262）。术后随访1～10年,所有患者术后进食、吞咽功能恢复良好,语言功能大多恢复良好。结论胸大肌肌皮瓣血供可靠,组织量丰富,且应用较灵活,可制作成肌皮瓣或肌瓣,对于晚期头颈肿瘤术后缺损是最优选择。     

胸大肌肌皮瓣在晚期头颈肿瘤术后组织缺损重建中的应用

背景与目的:晚期头颈肿瘤外科治疗时,留下的完全或者不完全的组织缺损,是目前头颈外科的一个难点。胸大肌肌皮瓣在头颈肿瘤术后组织缺损重建中仍起着不可替代的作用。本研究旨在探讨胸大肌肌皮瓣在头颈缺损重建中的适应指征,提高胸大肌肌皮瓣修复的成功率。方法:中山大学肿瘤防治中心2004年1月至2007年1月间共22例行胸大肌肌皮瓣重建头颈肿瘤术后缺损患者,其中颈部大面积皮肤缺损8例,口咽缺损4例,舌缺损5例,口底缺损3例,下咽缺损2例;13例患者采用血管蒂穿行锁骨下,9例经锁骨上转移至颈部;重建的最大面积为15cm×12cm,最小面积为8cm×5cm。结果:无手术死亡病例,1例出现皮瓣坏死,1例出现部分皮瓣坏死,皮瓣重建成功率为95.5%;手术后并发症伤口积血1例,口底瘘1例,并发症发生率为9.1%(2/22)。结论:胸大肌肌皮瓣是头颈肿瘤术后组织缺损重建的良好供区皮瓣,是颈部大面积皮肤缺损重建的首选皮瓣;血管蒂穿行锁骨下可以增加胸大肌肌皮瓣的修复半径,且有利于保护血管蒂不受压迫。     

134例头颈部肿瘤手术后缺损修复

目的：分析4种皮瓣修复头颈部缺损的效果、功能、并发症和供区创伤的大小，以为不同的缺损选择不同的皮瓣。方法：134例头颈部肿瘤患者，均行联合根治术加胸大肌肌皮瓣、颈阔肌肌皮瓣、额瓣、前臂皮瓣修复。结果：胸大肌皮瓣全部存活96例，部分坏死21例，坏死≥1／25例，全部坏死2例，颈阔肌皮瓣全部存活2例，部分坏死1例，全部坏死1例，4例额瓣和2例前臂皮瓣全部存活。结论：口腔及颈部大面积缺损需要胸大肌肌皮瓣修复，对需要洞穿修复的，尤其是女性，应尽量避免用胸大肌折叠瓣，可用复合瓣。对一般的口腔缺损用前臂皮瓣修复最为合适。     

胸大肌肌皮瓣用于咽喉晚期肿瘤术后一期修复

[目的]探讨胸大肌肌皮瓣在咽喉晚期肿瘤术后一期修复中的应用价值.[方法]对1996年6月到2004年6月55例咽喉晚期肿瘤根治术后一期应用胸大肌肌皮瓣修复的资料进行分析总结.其中舌根癌19例、扁桃体癌10例、喉咽癌9例、喉癌9例、鼻咽癌8例.术前放疗21例,术后放疗25例.胸大肌肌皮瓣修复咽喉部黏膜及黏膜下软组织缺损40例,修复颈部皮肤缺损15例.[结果]55例胸大肌肌皮瓣均一期修复完成.1例肌皮瓣皮肤完全坏死失败,3例肌皮瓣远端皮肤少许坏死重新清创缝合,修复成功率为98.2%(54/55).40例修复咽喉部黏膜缺损病人有3例进食轻度呛咳,1例进食吞咽不畅外均恢复吞咽功能,除全喉切除病人外均基本恢复语言功能.15例修复颈部皮肤缺损病人切口均愈合.3、5年存活率舌根癌为4/8,2/5;扁桃体癌为3/6,2/4;喉咽癌为2/4,1/3;喉癌为2/3,1/2;鼻咽癌为2/4,1/3.[结论]胸大肌肌皮瓣血供可靠,组织容量大,在咽喉部晚期肿瘤手术中应用可以提高存活率及病人术后生存质量,成功率高,是一期修复的理想材料.     

头颈肿瘤手术缺损胸大肌皮瓣修复的成活因素分析

目的：探讨头颈肿瘤组织缺损缺修复中影响胸大肌皮瓣的成活因素。方法：应用胸大肌复合肌皮瓣临床Ⅰ期修复晚期头颈恶性肿瘤患者手术缺损，结果：9例患者有7例胸大肌皮瓣全部成活，2例部分坏死伴瘘形成，结论：减少和消除影响术中和术后胸大肌血管蒂血流通畅的有关因素是保证其成活的关键。     

In situ carcinoma of the breast

The optimal management of ductal carcinoma in situ of the breast is controversial. With the introduction of the National Mammographic Breast Screening Programme the condition will be encountered more frequently. We have reviewed 76 patients from a 12-year period treated by one surgeon (R.W.B.) at the Nottingham City Hospital. Fifty-nine patients had either ductal carcinoma in situ or lobular carcinoma in situ; 17 patients had Paget's disease. The mean age at diagnosis was 54 years and the commonest mode of presentation was with a palpable breast lump. Pre-operative mammography was performed in 31 patients with ductal carcinoma in situ and 28 were reported as showing malignancy. Patients with a lesion in the breast parenchyma were treated either by mastectomy (simple, subcutaneous or 'wedge'--see text) or by lumpectomy and radiotherapy. Patients with Paget's disease were treated by simple mastectomy, wedge mastectomy or a cone excision of the nipple and underlying tissue. The mean follow-up period was 65 months. Patients treated by any of the procedures less than simple mastectomy had a significant chance of developing local recurrence. A detailed histological review was made and grade, microinvasion, calcification, necrosis and completeness of excision were assessed for each tumour. None of these factors was correlated with subsequent local recurrence.     

Correlation Between the In Vivo And In Vitro Antimicrobial Properties of Commercially Available Mouthwash Preparations

Summary

The effectiveness of six commercially available mouthwashes against common buccal organisms was studied. The minimum inhibitory concentrations (MIC) for two of the studied mouthwashes (Corsodyl and Oraldene) against buccal organisms were determined in Todd Hewitt medium with or without 5% serum. The concentration of the active substance in these two mouthwashes was in excess of the corresponding MIC. When the medium was supplemented with serum, lower MIC values were observed. Kill-time determinations, used at half the concentration of the normal preparation, revealed a rapid lethal effect for all tested mouthwashes. The slowest lethal effect was observed with Fluocaril mouthwash.

When mouthwashes were tested in volunteers, an immediate significant fall in salivary bacterial counts was produced by all except Fluocaril. With the latter mouthwash the decrease was significant 2-30 minutes after rinsing. The bacterial levels returned to pre-rinse levels after 30 minutes for Listerine, after 90 minutes for both Oraldene and Mint and after 180 minutes for Corsodyl, Fluocaril and Sansilla mouthwashes. The results indicate that there is a good correlation between in vivo efficacy and in vitro determination of all mouthwash preparations.